secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001725160-24-000177
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis appoints Julie Eastland CEO, succeeding Blackwell; plans registrational studies for azenosertib
--------------------------------------------------------------------------------

- Julie Eastland appointed CEO, President and Director effective Nov 13, 2024; succeeds Kimberly Blackwell who resigned as CEO but remains strategic advisor.
- Ingmar Bruns appointed Chief Medical Officer; Scott Myers appointed Board Chairperson.
- Cam Gallagher resigned as President/Interim CFO; Vincent Vultaggio named interim principal financial officer.
- Board approved amendment to 2022 Inducement Plan, increasing available shares by 5,500,000.
- Company plans to host investor event in Jan 2025 with updated azenosertib data and regulatory update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/0001725160-24-000177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000177/zntl-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer